Title	North Manchester General - Lipid Clinic
Organisations Involved	Amgen Limited and North Manchester General Hospital
Collaborative Working Project Description	Greater Manchester has the highest death rate from CVD in England – over twice the national average. The disease claims nearly 5,500 lives annually in the area, leading to an estimated loss of over 63,000 years of life. (1) The local lipid service at North Manchester General Hospital has identified that patients with suspected CV events attending A&E have not been routinely optimised. Therefore, patients at high cardiovascular risk may experience delays in accessing specialist lipid assessment and management. With this proposed Collaborative Working Project, North Manchester General Hospital will provide clinical expertise, service delivery, patient identification and triage, clinical governance and evaluation required to implement the project. Amgen will provide funding and project management support for the agreed project activities. The service will audit and identify high risk lipid patients and uncontrolled patients will be invited to attend the specialist lipid service, Patients will receive specialist assessment and guideline-directed lipid management in accordance with NICE guidance and local pathways. This service will aim to deliver sustainable and enhanced care to high-risk lipid and post ACS patients This will be achieved by: • Creating an additional lipid clinic 0.5 days per week for 8 months. • Data trawl to identify patients most at risk and those identified will be invited to attend the clinic. • Measuring and reviewing patients' lipids. • Offering lifestyle advice. • Triaging and referring appropriate patients for specialist assessment and management. • Following up patients as required. • Supporting implementation of NICE-guided lipid management where clinically appropriate. All treatment decisions will remain the responsibility of NHS clinicians and will be made in accordance with NICE guidance, local pathways and individual clinical judgement.

	The outputs of the project will inform the development of a business case to secure ongoing investment to future proof the service from rising demand.
Expected Outcomes	The service will aim to identify patients most at risk and through the service support appropriate specialist assessment and guideline directed management. The outputs from this will aim to show the value of this service, and to secure additional resources to counter increasing demand in the future. The expected outcomes will be: • Identification of most at risk patients with high lipids. • Increase the number of patients reviewed for lipids. • Increase the number of patients appropriately triaged and referred to the specialist lipid service in accordance with NICE guidance and local pathways. • Reduce the current waiting times for patients to receive testing and appropriate lipid management. • Increased specialist capacity and improved waiting times. • improved identification and triage of high-risk patients. Patients and the NHS will benefit from increased specialist capacity, improved identification and triage of high-risk patients, and reduced waiting times.

References:

(1) Health Innovation Manchester- Costs of cardiovascular disease in Greater Manchester in 2024 chrome-Extension://efaidnbmnnnibpcajpcglclefindmkaj/https://healthinnovationmanchester.com/wp-content/uploads/2025/06/Frontier-GM-CVD-costs-Final-report-04-02-25.pdf

GBR-NP-26-80071 August 2026